Mineralocorticoid receptor blockade--a novel approach to fight hyperkalaemia in chronic kidney disease
Authors:
Open Access
- 1 September 2013
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 6 (5) , 464-468
Abstract
Hyperkalaemia continues to be a major hazard of mineralocorticoid receptor blockade in an effort to retard the progression of chronic kidney disease (CKD). In cardiac patients on mineralocorticoid receptor blockade, RLY-5016 which captures K+ in the colon has been effective in reducing the risk of hyperkalaemia. This compound might be useful in CKD as well.Keywords
This publication has 64 references indexed in Scilit:
- Spironolactone ameliorates PIT1-dependent vascular osteoinduction in klotho-hypomorphic miceJournal of Clinical Investigation, 2013
- Visceral adipose tissue: emerging role of gluco‐ and mineralocorticoid hormones in the setting of cardiometabolic alterationsAnnals of the New York Academy of Sciences, 2012
- The use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonismJournal of Translational Medicine, 2011
- The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney diseaseBritish Journal of Clinical Pharmacology, 2011
- Eplerenone in Patients with Systolic Heart Failure and Mild SymptomsNew England Journal of Medicine, 2011
- Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trialEuropean Heart Journal, 2011
- Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trialDiabetologia, 2010
- A New Mode of Mineralocorticoid Receptor Antagonism by a Potent and Selective Nonsteroidal MoleculeJournal of Biological Chemistry, 2010
- Dietary Potassium Intake and Mortality in Long-term Hemodialysis PatientsAmerican Journal of Kidney Diseases, 2010
- Renal aspirin: will all patients with chronic kidney disease one day take spironolactone?Nature Clinical Practice Nephrology, 2008